Up to 30% off — ends 2 Aug
ONLY00h00m00s
Up to 30% off — ends 2 Aug
ONLY00h00m00s
Simon Haas
2 months ago
PhD Project: Targeting Transient Adaptations of Leukemic Stem Cells to Overcome Chemotherapy Resistance in Acute Myeloid Leukemia Heidelberg University in Germany
Degree Level
PhD
Field of study
Molecular Biology
Funding
Full funding availableDeadline
Aug 31, 2026
Country
Germany
University
Heidelberg University

How do I apply for this?
Sign in for free to reveal details, requirements, and source links.
Apply for this position
Keywords
Suggested positions
About this position
This funded PhD project at Heidelberg University focuses on overcoming chemotherapy resistance in acute myeloid leukemia (AML) by targeting transient adaptations of leukemic stem cells. AML is a highly aggressive blood cancer characterized by the accumulation of immature myeloid cells, leading to poor clinical outcomes and high relapse rates. While chemotherapy induces remission in most cases, relapse remains a significant challenge, often due to mechanisms beyond newly acquired mutations, such as metabolic and epigenetic adaptations.
The research will leverage a comprehensive collection of bone marrow and peripheral blood samples from a large patient cohort, spanning multiple treatment stages including induction chemotherapy, remission, relapse, and refractory disease. Using advanced single cell multiomic approaches and metabolic spectral flow cytometry, the project aims to identify transcriptomic and metabolic vulnerabilities in leukemic stem cells under standard therapy. Additionally, the role of extracellular vesicles, such as exosomes, in disease persistence and relapse will be investigated.
Functional validation of findings will be performed using pre-clinical models, including bone marrow organoids and xenotransplantation platforms. The project is embedded within the SFB1709 consortium, providing access to lectures, activities, and expertise in molecular stem cell, cancer, and translational research. Close collaboration partners include Prof. Dr. Simon Haas (Charite, Berlin), Dr. Lars Velten (CRG, Barcelona), Prof. Andreas Trumpp (DKFZ, HI-STEM, Heidelberg), and Prof. Carsten Müller-Tidow (Heidelberg University Hospital).
Applicants should have a Master’s degree or equivalent in biological sciences, with skills in molecular cell biology, single-cell technologies, and bioinformatics. Good English proficiency is required. The position offers full funding and is based at Heidelberg University Hospital, Department of Hematology, Oncology and Rheumatology, in Heidelberg, Germany. The application deadline is 31 August 2026, and the project is set to start on 1 October 2026.
To apply, submit your application through the HBIGS online portal. For further information, visit the project and consortium websites or contact the HBIGS office. This opportunity is ideal for motivated candidates seeking to contribute to cutting-edge cancer research in a collaborative and interdisciplinary environment.
Funding details
Full funding including tuition fees and living expenses is available for this position. The scholarship covers all educational costs and provides a monthly stipend.
How to apply
Please submit your application including a cover letter, CV, academic transcripts, and contact information for two references. Applications should be sent via the online portal before the deadline.
More information can be found here
Ask ApplyKite AI
Professors

How do I apply for this?
Sign in for free to reveal details, requirements, and source links.